On June 18, 2026, CervoMed Inc. entered into a Securities Purchase Agreement for a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, generating aggregate gross proceeds of $10.0 million. The offering is expected to close on or about June 22, 2026, with net proceeds intended for working capital and general corporate purposes. H.C. Wainwright & Co., LLC served as the exclusive placement agent, receiving a 6.0% cash fee, a 1.0% management fee, and warrants to purchase common stock equal to 6.0% of the shares issued at an exercise price of $5.00 per share. The company agreed to a 30-day lock-up period on further equity issuances and a six-month restriction on variable rate transactions. CervoMed Inc. is a biotechnology company that develops medical devices and therapies.
